NEW DELHI: US pharmaceutical giant Pfizer reported an 85% surge in net profit, reaching Rs 330.94 crore during the fourth quarter ending March 2025, driven by exceptional gains from completed asset sales and transfers, the company said in a regulatory filing.The company had posted a net profit of Rs 178.86 crore in the corresponding quarter of preceding fiscal, Pfizer Ltd said in the filing.Operational revenue reached Rs 591.91 crore in the quarter under review, compared to Rs 546.63 crore in the same period last year, it added.The fourth quarter’s total expenses increased to Rs 383.5 crore, up from Rs 377.9 crore in the previous year’s corresponding period.The quarter included an exceptional gain of Rs 172.81 crore, resulting from the completed transfer and sale of Thane property, including structures and buildings, to Zoetis Pharmaceutical Research Pvt Ltd.For the fiscal year ending March 31, 2025, the consolidated net profit reached Rs 767.6 crore, compared to Rs 551.33 crore in FY24.The company’s operational revenue for FY25 totalled Rs 2,281.35 crore, versus Rs 2,193.17 crore in FY24.The board of directors has proposed a total dividend of Rs 165 per equity share at Rs 10 each for the financial year ending March 2025.The dividend comprises a final dividend of Rs 35 per share, a special dividend of Rs 100 per share marking the company’s 75th year in India, and an additional special dividend of Rs 30 per share reflecting gains from the leasehold land and building transfer.
